February 05, 2024
Psychedelic-assisted therapy is a growing avenue for addressing mental health conditions such as treatment-resistant depression, and more progress is expected in the coming years. On today’s episode of the Business Group on Health podcast, we’re joined by Andrew Penn, a leader in the study and practice of psychedelic-assisted psychotherapy.
Penn discusses the latest developments in the rapidly evolving world of psychopharmacology, including a drug application submitted to the Food and Drug Administration in late 2023, designed to treat post-traumatic stress disorder. Penn describes the patient experience during psychedelic- assisted therapy, the integral role of nurses in current and future care models, and projections for future treatment innovation.
Related Content:
- Innovation Showcase: Psychedelics and Ketamine for Mental Health Treatment: February 13, 2024: Register now
- Ketamine and Psychedelics as a Treatment for Mental Health Conditions: Employer FAQs
- Podcast: Are Psychedelics the Next Big Breakthrough in Mental Health Treatment?
SPEAKERS
Andrew Penn | Psychiatric Nurse Practitioner and Clinical Professor, University of California, San Francisco
LuAnn Heinen | Business Group on Health
Duration 44 min
